Short Bowel Syndrome Market Demand Forecast 2025 To 2032

Posté 2026-02-12 04:19:49

7KB

Market Overview:

The Short Bowel Syndrome Market comprises pharmaceutical treatments alongside nutritional care methods and surgical procedures which address SBS as a malabsorption condition resulting from substantial small intestine resection. The market consists of GLP-2 analogy (e.g., teduglutide) and parenteral nutrition and enteral nutrition and antidiarrheal agents and intestinal rehabilitation programs. SBS patients need individualized medical care that includes dietary changes and nutritional supplements and sometimes requires prolonged intravenous nutrition.

Key players:

Takeda Pharmaceutical Company Limited, Zorba Therapeutics, Inc., Enzo Biochem, Inc., Baxter International Inc., Fresenius Kabi AG, B. Braun Melsungen AG, Vifor Pharma, Shire Pharmaceuticals, Novartis AG, AbbVie Inc., Amgen Inc., Boehringer Ingelheim International GmbH, Eli Lilly and Company, Sanofi S.A., Johnson & Johnson Services, Inc.

Sample Link- https://www.trendbridgeinsights.com/industry-report/short-bowel-syndrome-market

Market segmentation:

Type

GLP-2
Growth Hormone
Glutamine

Distribution Channel

Hospital Pharmacies
Online & Retail Pharmacies

Mega Trend Connect:

This report offers deep insights into how mega trends such as digitalization, precision medicine, data-driven care delivery, and regulatory evolution are transforming pharmaceuticals. It further examines the impact of advanced technologies, platform-based models, automation, and interoperability across products and services within this segment. The report assesses regulatory complexity, adoption readiness, cost pressures, and ecosystem maturity shaping global market development.

Global Trade Outlook:

Global trade in pharmaceuticals is increasingly shaped by regulatory stringency, localization mandates, data sovereignty requirements, and public health policy priorities. Cross-border scalability is constrained by approval timelines, compliance variation, and infrastructure readiness, driving regionalized production, partnerships, and delivery models. Market access and competitiveness now depend on regulatory agility, localized execution, and compliance-by-design strategies.

Region Analysis:

North America leads the Short Bowel Syndrome Market through the United States because of its strong healthcare system and widespread use of parenteral nutrition and GLP-2 analogs as well as high disease awareness. The market expands because of pharmaceutical industry leaders and robust reimbursement systems.

Recent Developments:

In December 2024, Hanmi Pharmaceutical announced successful Phase 2 trial results for its GLP-2 analog HM15136 which operates through weekly dosing. The therapy exhibits robust safety results and strong effectiveness indicators which indicate its potential to become a future SBS treatment option.

F&Q:

Q1. What is the projected market size & growth rate of the Short Bowel Syndrome Market?

Short Bowel Syndrome Market was valued at USD 754 million in 2024 and is expected to reach to USD 1278 million by 2032, growing at a CAGR of 6.8% from 2025 to 2032.

Q2. What are the key driving factors for the growth of the Short Bowel Syndrome Market?

Short Bowel Syndrome Market is driven by Rising Prevalence of Gastrointestinal Surgeries & Conditions, Growing Use of Parenteral and Enteral Nutrition, Approval and Adoption of GLP-2 Analog Therapies, Pediatric Applications, High Cost of Treatment and Drugs, Complications of Long-Term TPN Use, Limited Patient Pool and Diagnostic Challenges, Dependency on Skilled Care, Pipeline of Novel Therapies, Telehealth and Home Care Support, Government Support for Rare Diseases, Pediatric SBS Programs and Awareness Campaigns, Regulatory Complexity for Orphan Drugs, Limited Access in Low-Income Countries, Management of Long-Term Side Effects, High Treatment Discontinuation Rates.

Q3. What are the top players operating in the Short Bowel Syndrome Market?

The major players in the market are Takeda Pharmaceutical Company Limited, Zorba Therapeutics, Inc., Enzo Biochem, Inc., Baxter International Inc., Fresenius Kabi AG, B. Braun Melsungen AG, Vifor Pharma, Shire Pharmaceuticals, Novartis AG, AbbVie Inc., Amgen Inc., Boehringer Ingelheim International GmbH, Eli Lilly and Company, Sanofi S.A., Johnson & Johnson Services, Inc.

Q4. What segments are covered in the Short Bowel Syndrome Market?

The Global Short Bowel Syndrome Market is segmented based on Type, Distribution Channel, and Geography.

About US: